285 related articles for article (PubMed ID: 29463236)
1. Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
Jiao XD; Ding C; Zang YS; Yu G
BMC Cancer; 2018 Feb; 18(1):206. PubMed ID: 29463236
[TBL] [Abstract][Full Text] [Related]
2. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Shibasaki M; Tanabe A; Toda T; Sakata H; Ijichi M; Kusaka K; Bandai Y
Gan To Kagaku Ryoho; 2015 Jun; 42(6):755-7. PubMed ID: 26199252
[TBL] [Abstract][Full Text] [Related]
4. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal carcinomatosis originating from advanced gastric cancer--a report of three cases and review of the literatures.
Kusumoto T; Kimura Y; Sugiyama M; Ohta M; Tsutsumi N; Sakaguchi Y; Ikejiri K; Oki E; Saeki H; Morita M; Ikeda T; Furuta T; Maehara Y
Fukuoka Igaku Zasshi; 2013 Nov; 104(11):456-63. PubMed ID: 24620642
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid cytology diagnosis of HER2-positive leptomeningeal carcinomatosis from HER2-positive metastatic gastric cancer: case report.
Cavanna L; Rocchi A; Gorgni S; Ambroggi M; Foroni RP; Ubbiali A; Civardi G
J Clin Oncol; 2011 May; 29(13):e367-8. PubMed ID: 21300922
[No Abstract] [Full Text] [Related]
8. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
[TBL] [Abstract][Full Text] [Related]
9. [A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Fujita Y; Mizuta N; Sakaguchi K; Nakatsukasa K; Imai A; Umeda Y; Hamaoka A; Morita M; Shouji M; Goto M; Taguchi T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1699-702. PubMed ID: 23152022
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
LaBonte MJ; Yang D; Zhang W; Wilson PM; Nagarwala YM; Koch KM; Briner C; Kaneko T; Rha SY; Gladkov O; Urba SG; Sakaeva D; Pishvaian MJ; Hsieh RK; Lee WP; Lenz HJ
Mol Cancer Ther; 2016 Sep; 15(9):2251-8. PubMed ID: 27325685
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
17. Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
Lavaud P; Rousseau B; Ajgal Z; Arrondeau J; Huillard O; Alexandre J; Hulin A; Goldwasser F
Breast Cancer Res Treat; 2016 May; 157(1):191-2. PubMed ID: 27106482
[No Abstract] [Full Text] [Related]
18. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
19. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal carcinomatosis of gastric adenocarcinoma.
Bulut G; Erden A; Karaca B; Göker E
Turk J Gastroenterol; 2011; 22(2):195-8. PubMed ID: 21796558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
